Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.

Endocrine-related cancer - 1 Oct 2013

Gild Matti L, Landa Iñigo, Ryder Mabel, Ghossein Ronald A, Knauf Jeffrey A, Fagin James A

Abstract excerpt

Inhibitors of RET, a tyrosine kinase receptor encoded by a gene that is frequently mutated in medullary thyroid cancer, have emerged as promising novel therapies for the disease. Rapalogs and other mammalian target of rapamycin (mTOR) inhibitors are effective agents in patients with gastroenteropancreatic neuroendocrine tumors, which share lineage properties with medullary thyroid carcinomas. The objective of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Mice, Transgenic
Share to Protein Kinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-ret

Share to Pyrimidines

Share to RNA, Small Interfering

Share to Thyroid Neoplasms

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 23828865
DOI: 10.1530/ERC-13-0085
PMCID: PMC4375728

Genes

RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.PMID 23828865Read ↗

Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.Semantic proximity Read ↗

mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid CarcinomaSemantic proximity Read ↗

BAY 43-9006 inhibition of oncogenic RET mutants.Semantic proximity Read ↗

PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma.Semantic proximity Read ↗

BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.Semantic proximity Read ↗

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.Semantic proximity Read ↗

Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cellsSemantic proximity Read ↗

Enhancing mTOR-targeted cancer therapySemantic proximity Read ↗

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.Semantic proximity Read ↗

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.Semantic proximity Read ↗

mTOR activation in medullary thyroid carcinoma with RAS mutation.Semantic proximity Read ↗

Anti-tumor activity of motesanib in a medullary thyroid cancer model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.